Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies
Chronic hepatitis C (CHC) is a liver disease characterized by infection with the hepatitis C virus (HCV) persisting for more than six months. Patients with CHC often stop pursuing the pegylated interferon (peg-IFN) and ribavirin (RBV) treatment because of the high cost and associated adverse effects...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863289/ |